Published in FASEB J on March 01, 2002
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med (2003) 1.80
Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J Immunol (2009) 1.25
Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family. Br J Pharmacol (2011) 0.88
Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8. Ann N Y Acad Sci (2011) 0.86
An oligodeoxynucleotide that induces differentiation of bone marrow mesenchymal stem cells to osteoblasts in vitro and reduces alveolar bone loss in rats with periodontitis. Int J Mol Sci (2012) 0.77
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 15.78
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 7.60
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol (2009) 6.97
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity (2009) 5.70
Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature (2009) 5.00
Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell (2013) 3.92
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol (2009) 3.58
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci U S A (2009) 3.05
Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol (2003) 2.87
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest (2009) 2.85
Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity (2013) 2.79
Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol (2003) 2.68
Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut (2010) 2.42
Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol (2004) 2.39
TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity (2008) 2.37
Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol (2005) 2.31
Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur J Immunol (2010) 2.30
Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J Virol (2005) 2.16
Structural and functional insights into 5'-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat Struct Mol Biol (2010) 2.13
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11
siRNA and isRNA: two edges of one sword. Mol Ther (2006) 2.02
Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci (2011) 1.96
CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res (2011) 1.89
Replication-dependent potent IFN-alpha induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. J Immunol (2004) 1.85
Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. Cell (2013) 1.82
Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol (2003) 1.76
Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol (2002) 1.76
Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem (2004) 1.61
An SNX10 mutation causes malignant osteopetrosis of infancy. J Med Genet (2012) 1.58
Approaching the RNA ligand for RIG-I? Immunol Rev (2009) 1.57
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res (2005) 1.49
Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol (2002) 1.47
SiRNA delivery with exosome nanoparticles. Nat Biotechnol (2011) 1.46
Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res (2003) 1.44
IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol (2004) 1.40
Cellular immunostimulation by CpG-sequence-coated DNA origami structures. ACS Nano (2011) 1.38
Dual modulation of osteoclast differentiation by lipopolysaccharide. J Bone Miner Res (2002) 1.34
Plasmacytoid dendritic cells: the key to CpG. Hum Immunol (2002) 1.28
The chase for the RIG-I ligand--recent advances. Mol Ther (2010) 1.27
Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol (2009) 1.25
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
Morphological and immunocytochemical characteristics indicate the yield of early progenitors and represent a quality control for human mesenchymal stem cell culturing. J Anat (2009) 1.24
T cell-independent, TLR-induced IL-12p70 production in primary human monocytes. J Immunol (2006) 1.23
Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol (2008) 1.21
CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood (2003) 1.19
Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol (2008) 1.18
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res (2013) 1.17
Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol (2002) 1.14
RIG-I detects infection with live Listeria by sensing secreted bacterial nucleic acids. EMBO J (2012) 1.14
The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig Dis Sci (2007) 1.12
The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther (2003) 1.11
Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res (2002) 1.08
ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol (2009) 1.08
Immunostimulatory RNA blocks suppression by regulatory T cells. J Immunol (2009) 1.07
CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur J Immunol (2005) 1.06
Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res (2011) 1.06
Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J Immunol (2009) 1.04
Exosomes as nucleic acid nanocarriers. Adv Drug Deliv Rev (2012) 1.04
CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via Toll-like receptor 9. J Biol Chem (2003) 1.04
Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res (2007) 1.04
CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int J Cancer (2011) 1.03
Staphylococcus aureus protein A triggers T cell-independent B cell proliferation by sensitizing B cells for TLR2 ligands. J Immunol (2007) 1.02
ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol (2011) 1.02
An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer (2011) 1.02
RNA recognition via TLR7 and TLR8. Handb Exp Pharmacol (2008) 1.01
Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis (2012) 1.01
D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine (2012) 1.01